On the other hand, two meta-analyses (Arnott et al., 2020; Qiu et al., 2020) based on placebo-controlled cardiorenal outcome trials have revealed that sodium glucose co-transporter 2 (SGLT2) inhibitors, a novel class of hypoglycemic agents, significantly reduced various cardiovascular and renal outcomes in patients with T2D, regardless of patients with or without cardiorenal diseases. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.